Drawing for FOSUN PHARMA

USPTO serial 79407348

FOSUN PHARMA

Reviewed by CopyMark Law Group

Reg. 7971544Status 700Registered
Filing date
Status date
Registration date
Oct 7, 2025
Examiner
FRUM MILONE, MARCIE R
Law office
FILE REPOSITORY (FRANCONIA)

What this means

Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with FOSUN PHARMA?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

John Alumit

John Alumit ALUMIT IP135 S. Jackson Street, Suite 200Glendale, CA 91205United States

Goods and services

ClassDescriptionStatusFirst use
005Antiseptics; chemico-pharmaceutical preparations for the treatment of infectious-related diseases, auto-immune and inflammatory diseases, cardiovascular diseases, central nervous system diseases and pain, metabolic diseases, anti-viral diseases, oncologic diseases; anaesthetics; pharmaceutical preparations for the treatment of infectious-related diseases, auto-immune and inflammatory diseases, cardiovascular diseases, central nervous system diseases and pain, metabolic diseases, anti-viral diseases, oncologic diseases; vaccines; anti-inflammatory preparations; pharmaceuticals for the treatment of infectious diseases; pharmaceutical preparations to be inhaled for the prevention and treatment of respiratory diseases and disorders; pharmaceuticals for the treatment of cancer; balsamic preparations for medical purposes; drugs for medical purposes being pharmaceutical preparations for the treatment of infectious-related diseases, auto-immune and inflammatory diseases, cardiovascular diseases, central nervous system diseases and pain, metabolic diseases, anti-viral diseases, oncologic diseases; biological preparations for medical purposes being pharmaceutical preparations for the treatment of infectious-related diseases, auto-immune and inflammatory diseases, cardiovascular diseases, central nervous system diseases and pain, metabolic diseases, anti-viral diseases, oncologic diseases; medicines for human purposes being pharmaceutical preparations for the treatment of infectious-related diseases, auto-immune and inflammatory diseases, cardiovascular diseases, central nervous system diseases and pain, metabolic diseases, anti-viral diseases, oncologic diseases; diagnostic reagents for medical purposes; pharmaceuticals for the treatment of viral diseases; diagnostic preparations for medical purposesACTIVE—
010Medical apparatus and instruments for use in treating all treatable diseases, illnesses, and medical conditions for humansACTIVE—
035Retail store or wholesale store services for medical supplies; retail store or wholesale store services for medicines; retail store or wholesale store services for pharmaceutical preparations; marketing services; sales promotion for othersACTIVE—
042Pharmaceutical drug development; pharmaceutical research; conducting clinical trials for othersACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Apr 30, 2026FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
Apr 12, 2026FICSFINAL DISPOSITION NOTICE SENT TO IB—
Apr 12, 2026FIMPFINAL DISPOSITION PROCESSED—
Apr 9, 2026OPNXNOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB—
Mar 23, 2026OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Mar 23, 2026OPNRNOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB—
Jan 7, 2026FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Oct 7, 2025NRCCNOTICE OF REGISTRATION CONFIRMATION EMAILED—
Oct 7, 2025R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Oct 3, 2025NRCCNOTICE OF REGISTRATION CONFIRMATION EMAILED—
Aug 19, 2025NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Aug 19, 2025PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Aug 13, 2025NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Jul 15, 2025CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jul 15, 2025XAECEXAMINER'S AMENDMENT ENTERED—
Jul 15, 2025GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Jul 15, 2025GNEAEXAMINERS AMENDMENT E-MAILED—
Jul 15, 2025CNEAEXAMINERS AMENDMENT -WRITTEN—
Jul 7, 2025TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jul 7, 2025CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jul 7, 2025TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Apr 19, 2025RFNTREFUSAL PROCESSED BY IB—
Apr 3, 2025RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Apr 3, 2025RFRRREFUSAL PROCESSED BY MPU—
Feb 28, 2025RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Feb 27, 2025CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Dec 29, 2024DOCKASSIGNED TO EXAMINER—
Oct 25, 2024MAFRAPPLICATION FILING RECEIPT MAILED—
Oct 25, 2024NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Oct 24, 2024REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance